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New Aminocoumarin Antibiotics Formed by a Combined
Mutational and Chemoenzymatic Approach
Utilizing the Carbamoyltransferase NovN
was identified in the novobiocin gene cluster. Its function
was experimentally confirmed by the heterologous ex-
pression of novN in a mutant of the coumermycin pro-
ducer, Streptomyces rishiriensis, resulting in the forma-
tion of a carbamoylated coumermycin derivative [8].




Auf der Morgenstelle 8
72076 Tu¨bingen However, the yield was low [8], and no carbamoylated
clorobiocin derivatives could be detected after expres-Germany
sion of novN in a cloN2-defective mutant of the clorobio-
cin producer, Streptomyces roseochromogenes (our
unpublished data). It appears that insufficient availabilitySummary
of the substrate carbamoyl phosphate, rather than the
specificity of the carbamoyltransferase, has limited theFive new aminocoumarin antibiotics were produced
formation of carbamoylatd products in these experi-by a combined mutational and chemoenzymatic ap-
ments. Therefore, expression of NovN in vivo seems notproach. For this purpose, the 3″-carbamoyltransferase
to be a promising method to obtain new carbamoylatedNovN from the novobiocin producer Streptomyces
aminocoumarin antibiotics in useful quantities.spheroides was overexpressed in the heterologous
Recently, NovN was successfully overexpressed ashost S. lividans as an N-terminal His6 fusion protein
an N-terminal His8 fusion protein in E. coli and used forand purified by nickel affinity chromatography. Five
in vitro formation of novobiocin from 3″-descarbamoyldifferent 3″-unsubstituted aminocoumarin derivatives
novobiocin [9]. Furthermore, our group has been ablewere isolated from mutants of the clorobiocin producer
to create mutants of the clorobiocin producer that accu-S. roseochromogenes, carrying single or multiple gene
mulate 3″-unsubstituted clorobiocin derivatives, i.e.,defects. All five compounds were readily accepted as
compounds lacking the pyrrole-2-carboxyl moiety [10].substrates by NovN, and the 3″-carbamoylated prod-
These compounds represent interesting new substratesucts were isolated on a preparative scale. Their struc-
for the carbamoyltransferase NovN, setting the stagetures were elucidated by 1H-NMR and mass spectros-
for the in vitro production of new carbamoylated amino-copy, and their inhibitory activity on gyrase in vitro as
coumarin antibiotics.well as their antibacterial activity was determined. The
We here report the generation of further 3″-unsubsti-results give further insight into the structure-activity
tuted clorobiocin derivatives by specific mutagenesis ofrelationships of aminocoumarin antibiotics.
the clorobiocin producer, the overexpression and purifi-
cation of NovN by a convenient method using Strepto-
Introduction myces lividans as host, the chemoenzymatic synthesis
of new carbamoylated clorobiocin derivatives using
The aminocoumarin antibiotics novobiocin and clorobi- NovN, and the testing of these compounds for gyrase
ocin (structures see Table 1) as well as the related cou- inhibition and antibacterial activity.
mermycin A1 are potent inhibitors of DNA gyrase. They
compete with ATP for binding to the B subunit of this
enzyme and inhibit the ATP-dependent DNA supercoil- Results
ing catalyzed by gyrase [1]. X-ray crystallographic analy-
sis showed that the acyl moieties attached to the 3″- Production of 3″-Unsubstituted Clorobiocin
OH of the deoxysugar, i.e., a carbamoyl group in case Derivatives Using Specific Mutants
of novobiocin and a 5-methylpyrrole-2-carboxyl moiety of the Clorobiocin Producer
in case of clorobiocin, are important for the hydrogen cloN2 is involved in the transfer of the pyrrole-2-carboxyl
bonding network between the antibiotic and the GyrB moiety to the 3″-OH group of clorobiocin [10]. In a previ-
subunit [2, 3]. In addition, the chlorine atom at position ous study, we have inactivated the gene cloN2 in the
8 of the coumarin core of clorobiocin contributes to the clorobiocin producer by in-frame deletion. The resulting
higher biological activity of this compound in compari- mutant accumulated two 3″-unsubstituted clorobiocin
son to novobiocin, as 8-chlorinated compounds show derivatives, i.e., novclobiocin 104 and novclobiocin 105
at least a 2-fold higher inhibitory activity than 8-methyl- (Table 1) [10].
ated compounds [4]. This makes clorobiocin an interest- A similar strategy was now used to inactivate the gene
ing starting material for the development of new antibi- cloN2 in a clo-hal mutant of the clorobiocin producer,
otics. which accumulates clorobiocin derivatives lacking the
Our group has cloned and sequenced the biosynthetic chlorine atom. The plasmid pN2, containing an in-frame
gene clusters for novobiocin [5], coumermycin A1 [6], deletion in the coding sequence of cloN2, was intro-
and clorobiocin [7], all of which permit the development duced into protoplasts of the clo-hal mutant. Homolo-
of new aminocoumarin antibiotics by combinatorial bio- gous recombination led to a single crossover mutant
synthesis. A putative carbamoyltransferase gene novN (Figure 1A). Southern analysis proved the presence of
the disrupted gene cloN2 in the genome of strain XHC26
(Figure 1B). Chemical analysis showed that this mutant*Correspondence: shuming.li@uni-tuebingen.de
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hands expression in E. coli gave only low yields of activeTable 1. Chemical Structures of Aminocoumarin Derivatives
enzyme. It has been observed repeatedly that proteins
from Streptomyces strains that could not be well ex-
pressed in E. coli could be effectively expressed in
Streptomyces lividans [12–14]. Therefore, we expressed
NovN as an N-terminal His6 fusion protein in S. lividans
T7 (see Experimental Procedures). The protein yield was
quite high (6.7 mg/g cells, fresh weight), but much of
the protein was insoluble. The amount of soluble pro-
tein did not increase significantly when the growth tem-
perature was reduced to 20C. Nevertheless, sufficientCompound Name R1 R2 R3 R4
amounts of the His6-NovN fusion protein could be readily
purified from the soluble fraction by metal affinity chro-
matography. SDS-PAGE analysis showed the expected
band of 78 kDa (calculated mass 78.5 kDa) in the eluateClorobiocin
(Figure 2). An additional band appeared at 76 kDa that
had also been observed upon expression in E. coli [9]
Cl CH3
and may represent a degradation product. The protein
Novobiocin CH3 CONH2 CH3 yield of purified NovN was about 16 g/g cells (fresh
Novclobiocin 104a Cl H CH3 weight), determined by SDS-PAGE.
Novclobiocin 114b Cl CONH2 CH3
Novclobiocin 105a Cl H H
Novclobiocin 115b Cl CONH2 H Characterization of NovN
Novclobiocin 107a H H CH3 By using gel filtration, the molecular mass of native NovN
Novclobiocin 117b H CONH2 CH3 was determined as 79 kDa (calculated mass 78.5 kDa),Novclobiocin 108a H H H
indicating that the protein was active as a monomer. TheNovclobiocin 118b H CONH2 H
NovN reaction was strictly dependent on the presence ofNovclobiocin 283a Br Cl H CH3
Novclobiocin 284b Cl CONH2 CH3 ATP and divalent cations such as Mg2 or Mn2. The
optimal concentrations of both Mg2 and ATP werea Substrates for carbamoyltransferase assays
2 mM. The product formation in the carbamoyltrans-b Products of carbamoyltransferase assays
ferase assay showed a linear dependence on the protein
amount up to 0.5 M of purified protein and on incuba-
accumulated novclobiocin 107 (Table 1), which lacked tion time up to 90 min. The Km value for descarbamoyl
both the pyrrole moiety at 3″-OH and chlorine atom at novobiocin was determined as 2.4 M and turnover rate
position 8. In addition, another derivative, novclobiocin Kcat as 2.4 min1, similar to the data obtained for NovN
108 (Table 1) in which the methyl group at 4″-OH was expressed in E. coli [9].
also absent was accumulated.
The single crossover mutant created in this study con-
Chemoenzymatic Synthesis of Newtained both an inactivated copy and an intact copy of
Aminocoumarin AntibioticscloN2 (Figure 1). Integration of the vector sequence ap-
The five 3″-unsubstituted clorobiocin derivatives (i.e.,parently disrupted the transcription unit containing
novclobiocins 104, 105, 107, 108 as well as novclobiocincloN2 and additional genes involved in the biosynthesis
283) were used as substrates for carbamoylation. HPLCof the pyrrole moiety [8], as indicated by the lack of this
analysis revealed that all of them were readily acceptedstructural moiety in the metabolites accumulated by the
by NovN. As shown in Figure 3, 87% of novclobiocin 104mutant. Since a single crossover was sufficient to gener-
were converted to the carbamoylated derivative afterate the desired compounds, no further attempts were
overnight incubation under the assay conditions de-made to obtain double crossover mutants.
scribed in Experimental Procedures. The average con-The new compounds, novclobiocin 107 and 108, were
version rate of the other four substrates was about 54%.produced in amounts of 25.7 mg/l and 6.3 mg/l, respec-
The structures of the enzymatic substrates and productstively. They were extracted from the culture with ethyl
are given in Table 1. For structural elucidation, eachacetate, purified by preparative HPLC, and their struc-
product was isolated in preparative amounts and sub-tures were elucidated by 1H-NMR and mass spectros-
jected to 1H-NMR and MS analysis. Compared to thecopy (see Experimental Procedures).
parent compounds, the NMR spectra of the enzymaticA further 3″-unsubstituted compound, novclobiocin
products in CD3OD showed no additional proton signals283, was derived from a mutasynthetic experiment [11].
but marked downfield shifts of the signals of the protonsNovclobiocin 283 contained a bromine atom instead of
H-2″, H-4″, and especially H-3″ of the deoxysugar (Tablethe dimethylallyl moiety at position 3 of the 4-hydroxy-
2), indicating a substitution at position 3″of the deoxy-benzoyl moiety but otherwise had the same structure
sugar. FAB-MS analysis showed that the molecularas novclobiocin 104 (see Table 1).
mass of the enzymatic products was 43 Da larger than
that of the respective substrates, consistent with theOverexpression of NovN as an His6 Fusion Protein
attachment of a carbamoyl group.in Streptomyces lividans
Kinetic parameters were determined for novclobiocinNovN has been successfully overexpressed as an
N-terminal His8 tag protein in E. coli [9]. However, in our 104 and 105. Kcat values were determined as 1.32 min1
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Figure 1. Inactivation of cloN2 in the clo-hal Mutant
(A) Schematic representation of the gene inactivation.
(B) Southern blot analysis. Genomic DNA was restricted with PstI/PvuII. clo-hal mutant (lane 1), cloN2clo-hal double mutant XHC26 (lane
2). The indicated ScaI-EcoRI frament of 880 bp was used as a probe.
and 1.53 min1, respectively, similar to the value ob-
tained for descarbamoyl novobiocin. The Km value for
novclobiocin 104 (1.9 M) was similar to that of descar-
bamoyl novobiocin. In contrast, the Km for novclobiocin
105 was 14.3 M, i.e., five times higher than that of
genuine substrate, indicating that the 4″-methoxy group
may play a role in substrate binding. NovN was specific
for carbamoyl phosphate as substrate. With acetyl
phosphate, no product formation was observed.
Testing for Biological Activity
The new aminocoumarin derivatives were tested in vitro
for their inhibitory effect on E. coli gyrase in comparison
with the natural compounds novobiocin and clorobiocin.
The estimated IC50 of novobiocin resulted as 0.9 M,Figure 2. Analysis of Proteins Expressed in S. lividans T7 by 10%
and the activity of the other substances was expressedSDS-PAGE
relative to that of novobiocin (Figure 4). As observedLane 1, total protein before induction; lane 2, total protein after
previously [15, 16], clorobiocin was the most active sub-induction with 25g/ml thiostrepton for 24 hr; lane 3, soluble protein
after induction; lane 4, eluate from nickel affinity chromatography. stance in vitro, three times as active as novobiocin.
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in this assay. Otherwise, however, the antibacterial
assays largely confirmed the results of the in vitro gyrase
inhibition assays. Removal of the pyrrole carboxylic acid
moiety from clorobiocin resulted in a sharp drop of activ-
ity, and the additional removal of the methyl group at
4″-OH and/or the chlorine atom at position 8 further
reduced growth inhibition. Carbamoylation of novclobi-
ocin 104 led to an active antibacterial compound (nov-
clobiocin 114), which, however, was less active than
novobiocin or clorobiocin. Removal of the methyl group
at 4″-OH or of the chlorine atom at the 8 position or
replacement of the 3-dimethylallyl group by a bromine
atom strongly reduced the activity.
Discussion
Figure 3. HPLC Analysis of the Carbamoyltransferase Assays with The present study demonstrates the potential of a com-
Novclobiocin 104 as Substrate
bined mutational and chemoenzymatic approach for the
The assays were incubated overnight. (A) Assay with purified NovN.
generation of new amincouamrin antibiotics. In previous(B) Negative control with heat-denatured enzyme.
studies [4, 17, 18], our group has generated a variety
of new aminocoumarins by methods of combinatorial
biosynthesis, i.e., by combination of gene inactivationRemoval of the pyrrole carboxylic acid moiety from
clorobiocin resulted in a 100-fold drop of the activity and heterologous gene expression experiments. How-
ever, expression of the carbamoyltransferase NovN in(novclobiocin 104). The subsequent removal of the
methyl group at 4″-OH (novclobiocin 105), of the chlorine mutants of aminocoumarin antibiotic producers resulted
only in low yields of carbamoylated products [8]. In theatom at position 8 (novclobiocin 107), or of both these
substituents (novclobiocin 108) further reduced the ac- present study, we have overcome the problem by pro-
ducing 3″-unsubstituted aminocoumarin derivatives bytivity. When the pyrrole carboxylic acid moiety was re-
moved from clorobiocin and subsequently replaced by using specific mutants with single or multiple gene
defects followed by efficient carbamoylation of thesea carbamoyl group, activity was restored: the resulting
compound (novclobiocin 114) was nearly as active as compounds in vitro, which resulted in five new carba-
moylated aminocoumarin antibiotics in preparativenovobiocin but still four times less active than clorobio-
cin. In contrast, carbamoylation of novclobiocins 105, amounts.
The carbamoyltransferase NovN could readily be ob-107, and 108 led only to compounds of low activity
(novclobiocins 115, 117, and 118, respectively), proving tained in nearly pure form after expression of its struc-
tural gene in Streptomyces lividans. Although the naturalthe importance of the 4″-methoxyl group and the 8-
chlorine atom for gyrase inhibition. Replacement of the substrate of NovN is 3″-descarbamoyl novobiocin, the
enzyme readily accepted all five other aminocoumarin3-dimethylallyl moiety in novclobiocin 114 by a bromine
atom (novclobiocin 284) resulted in a 7-fold drop in ac- substrates tested in our study, showing that structural
variations can be introduced by this method in thetivity.
These results on the inhibition of gyrase in vitro were deoxysugar moiety, in the aminocoumarin moiety, and
in the benzoyl moiety of the antibiotics. On the othersubsequently confirmed by determination of the anti-
bacterial activity in a disc-diffusion assay by using Bacil- hand, acetyl phosphate was not accepted as substrate
by NovN, limiting the range of products to carbamo-lus subtilis as test organism (Figure 5). Activity was ex-
pressed relative to novobiocin. As observed previously ylated compounds.
Structural variation may be further increased by the[15], novobiocin showed higher activity than clorobiocin
Table 2. Comparison of 1HNMR Data of Aminocoumarin Derivatives
H-2″  (ppm), Multi (J/Hz) H-3″  (ppm), Multi (J/Hz) H-4″  (ppm), Multi (J/Hz)
Novclobiocin 104 4.12, t (3.1) 4.18, dd (3.1, 9.9) 3.40, d (9.9)
Novclobiocin 114 4.29, t (3.0) 5.37, dd (3.1, 10.1) 3.65, br s
Novclobiocin 105 4.13, br s 4.12, dd (3.1, 10.0) 3.76, d (10.0)
Novclobiocin 115 4.33, br s 5.27, dd (3.1, 10.3) 3.93, d (10.4)
Novclobiocin 107 4.02, t (3.1) 4.09, dd (3.1, 9.4) 3.37, d (9.4)
Novclobiocin 117 4.17, t (2.8) 5.25, dd (2.8, 8.8) 3.54a
Novclobiocin 108 4.04, br s 4.03, dd (3.4, 9.5) 3.73, d (9.5)
Novclobiocin 118 4.24, t (3.3) 5.15, dd (3.3, 10.0) 3.90, d (10.0)
Novclobiocin 283 4.11, s 4.19, dd (3.3, 9.9) 3.40, d (9.9)
Novclobiocin 284 4.27, t (3.1) 5.37, dd (3.1, 10.0) 3.55a
The NMR spectra were recorded at 400 MHz, in CD3OD. Abbreviations: t, triplet; d, doublet; dd, double doublet; s, singlet; and br, broad
signal; see table 1 for numbering of the structures.
a Overlapping with the signal of 3H-8″, J not determinable.
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Figure 4. In Vitro Inhibition of the DNA Supercoiling Reaction Catalyzed by E. coli Gyrase
IC50 values were estimated as described in the Experimental Procedures.
utilization of mutasynthetic strategies, as demonstrated the benzoyl moiety was fed to this mutant [15], resulting
in the formation of novclobiocin 283; finally, this com-by the generation of novclobiocin 284. First, the biosyn-
thesis of the natural benzoyl moiety was blocked by an pound was carbamoylated by chemoenzymatic meth-
ods by using NovN.inactivation experiment [19]; then, a synthetic analog of
Figure 5. Bioassay against Bacillus subtilis
Activities are expressed relative to novobiocin (100%).
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scribed elsewhere [11]. All the other reagents and chemicals wereThe compounds obtained in this study allowed us to
of analytical grade.obtain further insights into the structure-activity relation-
ships within the aminocoumarin class of gyrase inhibi-
Bacterial Strains, Vectors, and DNA Manipulation
tors by comparing their biological activities. Firstly, our The gene novN was cloned from cosmid 10-9C of the cosmid library
results confirmed the importance of the acyl moiety of the novobiocin producer Streptomyces spheroides NCIB 11891
attached to the 3″-OH of the deoxysugar. Lack of this [5]. Cloning experiments were performed in Escherichia coli XL1
Blue MRF’. The clo-hal mutant of S. roseochromogenes is de-acyl group led to a sharp reduction of activity. Novclobi-
scribed in Eusta´quio et al. [4]. The replicative vector pGM9 and theocin 114, which contained the carbamoyl instead of the
heterologous expression host S. lividans T7, possessing a thiostrep-pyrrole carboxylic acid group at 3″-OH but otherwise
ton-inducible T7 RNA polymerase gene, were kindly provided by
had an identical structure as clorobiocin, showed a W. Wohlleben (Tu¨bingen, Germany); S. lividans T7 was originally
4-fold lower inhibitory activity on gyrase than cloro- obtained from J. Altenbuchner (Stuttgart, Germany). The cloning
biocin. vector pGEM-T and the expression vector pRSET B were purchased
from Promega (Mannheim, Germany) and Invitrogen (Karlsruhe, Ger-Furthermore, our study demonstrates a crucial impor-
many), respectively. DNA manipulation and standard genetic tech-tance of the methyl group attached to the 4″-OH group
niques in E. coli and Streptomyces species were carried out asof the deoxysugar; lack of this group led to a strong
described previously [21, 22].
decrease of activity. In accordance with earlier results
[4], lack of the chlorine (or methyl) substituent at C-8 Inactivation of cloN2 in the clo-hal Mutant and Production
of the aminocoumarin ring also leads to a considerable of the 3″-Unsubstituted Clorobiocin Derivatives
decrease of activity. Novclobiocin 107 and 108
The clo-hal mutant was transformed with plasmid pN2 (Figure 1A),Interestingly, novclobiocin 284, which contains a bro-
which contained an in-frame deletion in the coding region of cloN2mine instead of the dimethylallyl moiety at C-3 of the
[10]. Thiostrepton-resistant colonies were selected and analyzed bybenzoyl moiety, not only showed lower antibacterial ac-
Southern blotting. While the clo-hal mutant gave a band of 3.33
tivity than novclobiocin 114, but also less gyrase inhibi- kb, strain XHC26 showed two bands of 2.35 kb and 2.69 kb, repre-
tion in vitro. This finding gives further experimental sup- senting the desired genotype of single crossover events (Figure 1B).
port to the hypothesis of Lafitte et al. [20] that the The wild-type, the clo-hal mutant, and the cloN2clo-hal double
mutant were cultured for the production of secondary metabolites,dimethylallyl moiety directly contributes to the binding
as described previously [7, 10, 23]. The culture was extracted twiceof the antibiotic to gyrase and not just facilitates the
with ethyl acetate and analyzed by HPLC with a Multosphere RP18-5uptake through the bacterial membrane as speculated
column (5 m, 250 4 mm; C S Chromatographie Service, Du¨ren,
earlier [2]. Germany) at flow rate of 1 ml/min by using a linear gradient from
70%–100% methanol in 1% aqueous formic acid over 25 min and
UV detection at 340 nm. Compared to the wild-type and the clo-
Significance hal mutant, two new peaks were found in the chromatogram of
the cloN2clo-hal double mutant. These two substances, desig-
Novobiocin and clorobiocin are potent inhibitors of nated as novclobiocin 107 and novclobiocin 108, were isolated on
a preparative scale by HPLC as described above. Their structuresbacterial DNA gyrase. We reported here a method to
were elucidated by MS and 1H-NMR. Negative fast atom bombard-generate new carbamoylated aminocoumarin deriva-
ment (FAB) mass spectra were recorded on a TSQ70 spectrometertives by a combined mutational and chemoenzymatic
(Finnigan, Bremen, Germany) by using diethylethanolamine as ma-
approach. The 3″-carbamoyltransferase NovN from trix. 1H-NMR spectra were measured on an AMX 400 spectrometer
the novobiocin producer Streptomyces spheroides (400 MHz; Bruker, Karlsruhe, Germany) by using CD3OD as solvent.
was overexpressed in S. lividans and purified to near MS and 1H-NMR spectral data were as follows (see Table 1 for
numbering of the structures; br, broad signal).homogeneity. Different 3″-unsubstituted aminocou-
Novclobiocin 107marin derivatives were isolated from mutants of the
Negative FAB-MS m/z (relative intensity in %): 554 (48, [M-H]),clorobiocin producer S. roseochromogenes, carrying
392(9), 379(20), 366(20), 336(7), 314(11), 283(11), 253(15), 237(11),
single or multiple gene defects. All these compounds 209(100), 207(39), 190(27); 1H-NMR: ppm 1.11 (s, 3H-6″), 1.33 (s,
were readily accepted as substrates by NovN, demon- 3H-7″), 1.74 (s, 3H-11), 1.75 (s, 3H-10), 3.34 (d, J  6.8 Hz, 2H-7),
strating that structural variation can be introduced by 3.37 (d, J  9.4 Hz, H-4″), 3.58 (s, 3H-8″), 4.02 (t, J  3.1 Hz, H-2″),
4.09 (dd, J1  9.4 Hz, J2  3.0 Hz, H-3″), 5.35 (tt, J1  7.4 Hz, J2 our method in the deoxysugar moiety, the aminocou-
1.2 Hz, H-8), 5.56 (d, J  2.3 Hz, H-1″), 6.85 (d, J  8.4 Hz, H-5),marin moiety, as well as in the benzoyl moiety. Testing
7.04 (complex overlapping signals, J not determinable, H-6, H-8),of biological activity of the 3″-carbamoylated products
7.72 (dd, J1  8.4 Hz, J2  2.2 Hz, H-6), 7.75 (d, J  2.2 Hz, H-2),gave further insights into the structure-activity rela- 7.89 (d, J  9.5 Hz, H-5).
tionships of aminocoumarin antibiotics, especially Novclobiocin 108
about the importance of the acyl moiety and the me- Negative FAB-MS m/z (relative intensity in %): 540(27, [M-H]),
415(7), 380(16), 352(11), 338(7), 314(15), 312(7), 283(24), 255(16),thoxy group at the deoxysugar. This work is another
209(100), 207(35), 191(8); 1H-NMR: ppm 1.14 (s, 3H-6″), 1.32 (s, 3H-example for generating novel, structurally modified
7″), 1.74 (s, 3H-11), 1.75 (s, 3H-10), 3.34 (d, J  7.3 Hz, 2H-7), 3.73compounds for drug discovery.
(d, J  9.5 Hz, H-4″), 4.03 (dd, J1,  9.5 Hz, J2  3.4 Hz, H-3″), 4.04
(br s, H-2″), 5.35 (br t, J  7.3 Hz, H-8), 5.58 (br s, H-1″), 6.84
(d, J  8.4 Hz, H-5), 7.04 (complex overlapping signals, J not deter-Experimental Procedures
minable, H-6, H-8), 7.72 (dd, J1  8.4 Hz, J2  2.2 Hz, H-6), 7.75
(br s, H-2), 7.90 (d, J  9.4 Hz, H-5).General Chemicals
Descarbamoyl novobiocin was kindly provided by Pharmacia & Up-
john, Inc. (Kalamazoo, MI). Carbamoyl phosphate dilithium salt Construction of pXHNEG for Expression of NovN as an
N-Terminal His6 Fusion Protein in S. lividans T7(CAP-Li2), lithium potassium acetyl phosphate, and adenosine
5-triphosphate dipotassium salt (ATP) were purchased from Sigma novN was amplified from cosmid 10-9C by using the GC-RICH PCR
system (Roche, Mannheim, Germany) with the primer pair novN-BclI(Taufkirchen, Germany). Novclobiocin 283 was obtained as de-
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(5-GTGCTCGCTGATCAGAACGACATG-3) and novN-HindIII (5- Novclobiocin 115
Negative FAB-MS m/z (relative intensity in %): 617(3, [M-H]), 524(2),AAGGGAAGCTTTACGGCCGCGAC-3). Introduced restriction sites
are underlined. The DNA fragment was directly ligated into the linear- 485(2), 462(6), 419(6), 388(6), 356(10), 314(16), 283(84), 255(61),
209(100); 1H-NMR: ppm 1.20 (s, 3H-6″), 1.32 (s, 3H-7″), 1.73 (s, 3H-ized vector pGEM-T, resulting in plasmid pXHNET. novN was re-
leased from pXHNET by digestion with BclI and HindIII and ligated 10, 3H-11), 3.34 (overlapping with the signal of CH3OH, 2H-7), 3.93
(d, J  10.4 Hz, H-4″), 4.33 (br s, H-2″), 5.27 (dd, J1  10.3 Hz, J2 into pRSET-B, which had been restricted with BamHI and HindIII,
to give plasmid pXHNER. To obtain the plasmid pXHNEG, pXHNER 3.1 Hz, H-3″), 5.35 (br s, H-8), 5.65 (br s, H-1″), 6.81 (br s, H-5),
7.21(br s, H-6), 7.73 (br s, H-6), 7.77 (s, H-2), 7.90 (br s, H-5).was fused with the vector pGM9 via the restriction site HindIII.
pXHNEG contained a kanamycin resistance gene. Novclobiocin 117
Negative FAB-MS m/z (relative intensity in %): 597(6, [M-H]), 554(2),
491(2), 427(2), 411(7), 370(7), 307(9), 306(29), 258(37), 257(69),
Expression of pXHNEG and Purification 209(100), 207(25); 1H-NMR: ppm 1.17 (s, 3H-6″), 1.35 (s, 3H-7″),
of Carbamoyltransferase 1.73 (s, 3H-10, 3H-11), 3.34 (overlapping with the signal of CH3OH,
After transforming S. lividans T7 protoplasts with plasmid pXHNEG, 2H-7), 3.54 (complex overlapping signals, 3H-8″, H-4″), 4.17 (t, J 
cells were regenerated on R2YE plates and kanamycin- and thio- 2.8 Hz, H-2″), 5.25 (dd, J1  8.8 Hz, J2  2.8 Hz, H-3″), 5.35 (br t,
strepton-resistant colonies were selected. They were grown in J  7.2 Hz, H-8), 5.55 (d, J  2.5 Hz, H-1″), 6.81 (d, J  8.4 Hz, H-5),
YEME medium with kanamycin (10 g/ml) at 28C for 48 hr, and 6.97 (complex overlapping signals, J not determinable, H-6, H-8),
then 1 ml culture was transferred to 100 ml new YEME medium with 7.71 (dd, J1  8.4 Hz, J2  2.2 Hz, H-6), 7.76 (br s, H-2), 7.91 (d, J 
kanamycin (10 g/ml) and thiostrepton (25 g/ml) and cultured for 9.0 Hz, H-5).
further 24 hr. The cells were harvested by centrifugation (10 min at Novclobiocin 118
5000  g) and incubated in ice-cold lysis buffer (50 mM NaH2PO4 Negative FAB-MS m/z (relative intensity in %): 583(10, [M-H]),
(pH 8.0), 300 mM NaCl, 15 mM imidazole, 0.2% triton 100, and 540(6), 522(2), 462(5), 402(5), 380(6), 325(6), 314(13), 283(97), 255(70),
6 mg/ml lyzozyme) for 30 min. The cell suspension was sonicated 209(100); 1H-NMR: ppm 1.20 (s, 3H-6″), 1.34 (s, 3H-7″), 1.74 (s, 3H-
for 8 min (Branson Sonifier 250) and the cell debris was removed 10, 3H-11), 3.34 (overlapping with the signal of CH3OH, 2H-7), 3.90
by centrifugation (30 min at 15,000  g). The protein was purified (d, J  10.0 Hz, H-4″), 4.24 (t, J  3.3 Hz, H-2″), 5,15 (dd, J1  10.0
from the soluble cell extract by metal affinity chromatography by Hz, J2  3.3 Hz, H-3″), 5.35 (br t, J  7.2 Hz, H-8), 5.57 (d, J  2.2
using Ni-nitrilotriacetic acid (Ni-NTA) resin (Qiagen, Hilden, Ger- Hz, H-1″), 6.82 (d, J  8.4 Hz, H-5), 7.00 (complex overlapping
many) according to the manufacturer’s instructions. Subsequently, signals, J not determinable, H-6, H-8), 7.71 (dd, J1  8.4 Hz, J2 
the Ni-NTA resin eluate was applied onto a NAP 10 column (Amer- 2.2 Hz, H-6), 7.76 (s, H-2), 7.91 (d, J  9.3 Hz, H-5).
sham Biosciences, Freiburg, Germany) and eluted with 0.2 M Tris- Novclobiocin 284
HCl (pH 8.0). Negative FAB-MS m/z (relative intensity in %): 643(2, [M-H]), 569(2),
524(6), 491(3), 463(6), 419(6), 356(10), 314(25), 283(37), 253(41),
209(100); 1H-NMR: ppm 1.17 (s, 3H-6″), 1.32 (s, 3H-7″), 3.55 (com-
Protein Analysis plex overlapping signals, J not determinable, H-4″ and H-8″), 4.27
Protein concentrations were determined by the Bradford method (t, J  3.1 Hz, H-2″), 5.37 (dd, J1  10.0 Hz, J2  3.1 Hz, H-3″), 5.63[24] by using bovine serum albumin as a standard. SDS-PAGE was (d, J  1.8 Hz, H-1″), 6.94 (d, J  8.4 Hz, H-5), 7.19 (d, J  8.1 Hz,
carried out according to the method of Laemmli [25], and protein H-6), 7.87 (overlapping signals of H-6 and H-5), 8.19 (br s, H-2).
bands were stained with Coomassie brilliant blue R250. The molecu-
lar mass of native NovN was determined by gel filtration on a HiLoad
Determination of Biological Activity26/60 Superdex 200 column by using 50 mM Tris-HCl buffer (pH
The carbamoylated aminocoumarin derivatives were tested for in-8.0) containing 150 mM NaCl, 5 mM dithiothreitol, and 50M phenyl-
hibitory effect on supercoiling activity of E. coli gyrase by using themethylsulfonyl fluoride. The column was calibrated with blue dextran
DNA gyrase kit from John Innes Enterprises Limited (John Innes2000, aldolase (Mr 158,000), albumin (Mr 66,000), ovalbumin (Mr Centre and Norwich Research Park, Colney, Norwich) according to45,000), and ribonuclease A (Mr 13,700) (Amersham Biosciences, the manufacturer’s instruction. IC50 was defined as the concentrationFreiburg, Germany).
at which the DNA gyrase supercoiling activity was inhibited by 50%.
Antibacterial activity against Bacillus subtilis ATCC 14893 was
determined by a disc-diffusion assay, as described elsewhere [4,Enzyme Assay and Identification of the Enzymatic Products
17], by using filter paper disks of 3 mm diameter.The carbamoyltransferase assay mixture contained 0.2 M Tris-HCl
(pH 8.0), 1 mM descarbamoyl novobiocin or analogs, 5 mM CAP-
AcknowledgmentsLi2, 2 mM ATP, 2 mM Mg2, and purified NovN (0.4 M) in a final
volume of 100 l. The reactions were carried out at 30C and termi-
We thank Anthony Maxwell and John Innes Enterprises Limitednated by the addition of 5 l 1.5 M trichloroacetic acid. Kinetic
(John Innes Centre and Norwich Research Park, Colney, Norwich)parameters were determined with 37.5 nM NovN over 5 min. The
for providing the DNA gyrase assay kit. The Streptomyces lividans T7assay products were extracted with ethyl acetate. After evaporation
strain and novclobiocin 283 were kindly provided by W. Wohllebenof the organic solvent, the residue was dissolved in methanol and
(Tu¨bingen, Germany) and Ute Galm (Tu¨bingen, Germany), respec-analyzed by HPLC with the same gradient as described for analysis
tively. H. Xu received a graduate student scholarship from Bundes-of novclobiocin 107 and 108. UV absorption was recorded at 325
land Baden-Wu¨rttemberg, Germany.nm. For preparative experiments, the assay mixtures were incubated
overnight, and the enzymatic products were isolated by HPLC and
subjected to MS and 1H-NMR analysis. Received: December 3, 2003
MS and 1H-NMR spectral data were as follows (see Table 1 for Revised: February 5, 2004
numbering of the structures; 1H-NMR at 400 MHz, with CD3OD as Accepted: February 6, 2004
the solvent; br, broad signal). Published: May 21, 2004
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